How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Cynthia Dunbar, Dr. Janis Abkowitz, Dr. Nancy Berliner, and Dr.
Susan Shurin discuss the concerted grassroots effort to nominate women
for ASH awards.
Dr. Abkowitz pens her last President's Column as ASH President, focusing on ASH's collaboration with the Wallace H. Coulter Foundation.
ASH as Your Partner in Quality ImprovementImproving the quality of care delivered to patients with hematologic diseases is the most important mandate for clinicians practicing in our specialty. The need for quality improvement in health care has been detailed in
Maintaining a Sense of Community Within ASHASH’s strengths are our diversity and that we are a single voice for a broad field. However, while ASH continues to provide resources and services for hematologists in all areas, the enormous growth in
President's Column Sickle Cell Trait and Sports Is the NCAA a Hematologist?In 2006, Dale Lloyd Jr., a 19 year old freshman at Rice University who played defensive back, died one day after collapsing during football practice. It is an event
Mentorship is a Core Value of ASH“The mind is not a vessel to be filled, but a fire to be kindled.” This quote is attributed to Plutarch (born 46 A.D.) as a variant translation of his statements in On Listening
Fighting for Hematology ResearchIt is an absolute honor to write as president of ASH, and I am especially honored to be your leader at this complex time when our challenges as hematology clinicians and researchers are huge, but when the
Clement A. Finch, MD (1915 2010)Clement A. Finch, MD, eighth president of the American Society of Hematology, died on June 28, 2010, just six days shy of his 95th birthday. Clem, as he was known, was the first head of
Human embryonic stem (ES) cells are derived from early embryos and are capable of differentiating into all tissues. Although they are excellent tools for research and have broad therapeutic promise, their procurement, manipulation, and use raise major ethical issues.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology